Marzo-Ortega, Helena http://orcid.org/0000-0002-9683-3407
Navarro-Compán, Victoria
Akar, Servet
Kiltz, Uta
Clark, Zoë
Nikiphorou, Elena
Funding for this research was provided by:
UCB Pharma
Article History
Received: 24 March 2022
Revised: 17 May 2022
Accepted: 24 May 2022
First Online: 28 June 2022
Declarations
:
: The authors have no relevant conflicts of interest or disclosures relevant to this work. Outside of this work:HMO: received grants from Janssen, Novartis, Pfizer and UCB Pharma and honoraria from AbbVie, Biogen, Celgene, Janssen, Eli Lilly, Novartis, Takeda and UCB Pharma. HMO is supported by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (LBRC).VNC: received grants from AbbVie and Novartis and honoraria from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer and UCB Pharma.SA: received grant/research support from, been a consultant for, and served on the speaker’s bureau for AbbVie, Eli Lilly, Janssen, MSD, Novartis, Pfizer and UCB Pharma.UK: received grant and research support and consultancy fees from AbbVie, Amgen, Biocad, Biogen, Chugai, Eli Lilly, Fresenius, Gilead, Grünenthal, GSK, Janssen, MSD, Novartis, Pfizer, Roche, UCB Pharma and Viatris.ZC: current employee of the National Axial Spondyloarthritis Society (NASS). NASS have received grant funding from AbbVie, Biogen, Eli Lilly, Janssen, Novartis and UCB Pharma.EN: received speaker honoraria/participated in advisory boards for AbbVie, Celltrion, Eli Lilly, Galapagos, Gilead, Pfizer and Sanofi and holds research grants from Eli Lilly and Pfizer.
: All views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any institution or association.